What Does a Chromogranin A Level Over 300 Mean?

A chromogranin A (CgA) level above 300 is markedly elevated and raises serious concern for a neuroendocrine tumor (NET), though it does not guarantee one. In one widely cited study, CgA levels exceeding 300 µg/L appeared in about 40% of patients with confirmed neuroendocrine tumors but only 2% of controls without them.¹ That said, a handful of non-cancer conditions can push CgA that high, and the number itself depends heavily on which laboratory assay was used. Understanding what drives such a result, and what does not, is essential for making sense of it.

What Chromogranin A Actually Is

CgA is a protein stored inside the small sacs (secretory granules) that hormone-producing cells use to package and release their chemical signals. It serves double duty: it acts as a structural scaffold that helps granules form and it gets chopped into smaller peptides that have their own biological effects on the cardiovascular and immune systems.² Because CgA is released into the bloodstream alongside the hormones it was stored with, measuring it gives a rough readout of how active those neuroendocrine cells are. Healthy people have detectable CgA in their blood, but certain tumors and diseases amplify its release dramatically.

Normal Reference Ranges and Why They Vary

There is no single universal “normal” number for CgA. Levels depend on the test kit, the patient’s age, sex, and kidney function. One large study that established age- and sex-stratified reference values found that the 97.5th percentile (the upper boundary of normal for most people) ranged from about 64 ng/mL in younger women to roughly 94 ng/mL in older adults of either sex.³ In children, plasma CgA runs higher than in adults, with an upper reference limit reaching 118 µg/L in infants under three and gradually falling to adult-range values through adolescence.⁴ One hospital in Oman used a cut-off of 22 IU/L for the same analyte.⁵ The units alone (ng/mL versus µg/L versus IU/L) hint at the problem: results from one assay cannot be compared directly with results from another.

Against that background, a value over 300 in any commonly used assay sits far above the normal ceiling. Its significance depends on what is causing the elevation, but the distance from normal is large enough that your clinician will almost certainly pursue additional testing.

Neuroendocrine Tumors Are the Primary Concern

CgA is considered the best general blood marker for neuroendocrine tumors because these tumors are packed with the same secretory granules that store CgA. A meta-analysis pooling data from multiple studies found that circulating CgA detects NETs with a sensitivity of about 73% and a specificity of about 95%.⁶ That specificity figure means false positives are uncommon, though not impossible.

Among NET subtypes, the ones most likely to produce very high CgA include gastrinomas (elevated in essentially all cases), pheochromocytomas (elevated in roughly nine out of ten), carcinoid tumors of the gut and lung (about 80%), nonfunctioning pancreatic NETs (about 70%), and medullary thyroid carcinomas (about half).¹ The highest absolute values tend to appear in patients with carcinoid tumors. CgA also correlates with tumor burden: patients with gastroenteropancreatic NETs who had metastatic disease had a median CgA roughly twice that of patients whose tumors were still localized.⁷ In childhood neuroblastoma, a related neuroendocrine malignancy, serum CgA parallels disease stage and predicts survival.⁸

So a CgA above 300 does not tell you which tumor you are dealing with, but it strongly narrows the field toward neuroendocrine cancers, and it hints that the tumor burden may not be small.

Non-Cancer Causes That Can Push CgA Very High

The tricky part is that several common, non-malignant conditions raise CgA, sometimes dramatically. Clinicians need to rule these out before assuming a tumor is responsible.

Kidney Failure

The kidney is a major site where CgA fragments are cleared from the blood. When kidney function declines, CgA accumulates. In patients with advanced renal failure (filtration rate below 20 mL/min), CgA levels rose roughly 22-fold compared with people who had normal kidney function.⁹ That magnitude of increase can easily push values well past 300 even without any tumor. Researchers have stressed that kidney function must be accounted for whenever CgA is used diagnostically, because the buildup occurs regardless of the underlying cause of renal disease.¹⁰ In patients with impaired creatinine clearance, the ability of CgA to specifically identify a pheochromocytoma drops sharply.¹¹

Proton Pump Inhibitors

PPIs like omeprazole and pantoprazole are among the most prescribed drugs worldwide. By suppressing stomach acid, they cause the stomach hormone gastrin to rise, which in turn stimulates the enterochromaffin-like cells of the stomach lining. Those cells are neuroendocrine cells, and they release CgA.¹² The elevation can be meaningful: CgA rises significantly even after just five days of PPI therapy.¹³ In long-term users, the effect is more pronounced and can create a false-positive scare. That is why many clinical protocols ask patients to stop PPIs (or switch to an H2-receptor blocker) for at least two weeks before retesting CgA.¹⁴ If you are on a PPI and receive a high CgA result, this is one of the first things your doctor should consider.

Heart Disease and Other Conditions

CgA is also elevated in several cardiovascular conditions. Heart failure, coronary artery disease, and chronic hypertension can all raise circulating CgA, reflecting heightened sympathetic nervous system activity and changes in how the heart processes the protein.¹⁵ Inflammatory bowel disease (IBD) is another contributor; over half of IBD patients with active disease had CgA above the normal range in one study, and CgA tracked with TNF-alpha, a marker of systemic inflammation.¹⁶ The broader pattern is that any condition involving increased neuroendocrine cell activity, whether from a tumor or from chronic disease, can raise CgA.¹⁷

While these non-cancer causes can produce elevated readings, they rarely produce levels in the hundreds unless kidney failure is involved. A CgA well above 300 in someone with normal kidneys and no PPI use tilts the odds heavily toward a NET.

Why the Lab Assay Matters More Than You Might Think

One of the most frustrating aspects of CgA testing is that results can vary by roughly 25% depending on which commercial assay kit is used.¹⁸ Different kits use different antibodies that recognize different parts of the CgA molecule, and there is no universal calibration standard. A head-to-head comparison of three widely used kits found that their sensitivity ranged from 67% to 93% and their specificity ranged from 85% to 96%.¹⁹ In practical terms, this means a CgA of 320 on one assay and a CgA of 250 on another could represent the same amount of protein in the blood.

The clinical consequence is straightforward: if you are being monitored over time, every blood draw should be run on the same assay at the same lab. Switching assays midway through follow-up makes it impossible to know whether a change in the number reflects a change in your disease or just a change in measurement technique.²⁰ If your report does not specify the assay and its reference range, ask.

The Hook Effect and Falsely Low Readings

There is an unusual technical pitfall that cuts the other direction. Some CgA assays suffer from a “high-dose hook effect,” where extremely high concentrations of the protein paradoxically saturate the test and produce a falsely low or normal result. One study found this apparent hook effect in about 15% of specimens tested on certain commercial assays.²¹ This matters because a patient with a large, CgA-secreting tumor might get a reassuringly low reading. If clinical suspicion is high but the CgA does not match, the lab can dilute the sample and retest to check for this artifact. Newer assay designs have been engineered to avoid the problem, but not all labs have adopted them.

What Happens After a CgA Above 300

A single elevated CgA result does not lead straight to a diagnosis. The typical next steps involve ruling out the common confounders and then imaging.

Medication review: If you are taking a PPI, your doctor will likely stop it or switch you to an alternative acid-reducing drug for about two weeks, then recheck CgA.
Kidney function: A basic metabolic panel or estimated glomerular filtration rate clarifies whether impaired clearance is inflating the number.
Repeat measurement: CgA can fluctuate. A second draw on the same assay confirms the elevation is real and not a one-off spike.
Imaging: If the elevated level persists after confounders are addressed, cross-sectional imaging (CT or MRI) of the chest, abdomen, and pelvis is standard. For suspected NETs, somatostatin receptor-based imaging such as a Ga-68 DOTATATE PET/CT scan is especially sensitive for localizing tumors and detecting metastatic spread.
Additional biomarkers: Depending on symptoms, clinicians may order a 24-hour urine collection for 5-hydroxyindoleacetic acid (the main breakdown product of serotonin) to look for a carcinoid tumor, or test plasma metanephrines if pheochromocytoma is suspected.²²

The goal of this workup is not just to find a tumor but to characterize it: where it is, how large, whether it has spread, and what grade it is. CgA level alone cannot answer those questions, but it can frame how urgently the answers are needed.

Using CgA for Monitoring After Diagnosis

Once a NET is confirmed, CgA becomes a tracking tool rather than a diagnostic one. Serial measurements help clinicians gauge whether treatment is working. CgA levels correlate with tumor burden, so a falling CgA after surgery or during therapy is generally a good sign, while a rising CgA can signal disease progression.²³ One retrospective analysis found that CgA started climbing about six months before radiological progression became visible on imaging in pancreatic NETs, offering an early warning window.²⁴ The same caveat about assay consistency applies here: trends are only interpretable if every sample runs through the same test platform.

CgA is not the only marker clinicians watch. For gastroenteropancreatic NETs, tumor grade and imaging findings carry at least as much weight. But a doubling or tripling of CgA between visits, especially when it was trending down, is the kind of signal that prompts an earlier-than-scheduled scan.

CgA in Pregnancy

Pregnancy raises CgA naturally, which creates an interpretive headache if a NET is suspected in a pregnant patient. In one study, maternal CgA at term tended to be higher than in early pregnancy or in non-pregnant women, and CgA in umbilical cord blood was substantially higher still.²⁵ This does not mean a high CgA in a pregnant person should be ignored, but it does mean the usual reference ranges do not apply, and the threshold for alarm needs to be recalibrated.

CgA’s Broader Biology Beyond Diagnosis

CgA is more than a passive tumor marker. The protein is a precursor: enzymes cleave it into multiple smaller peptides, each with distinct activities. Some of these fragments regulate blood pressure, others modulate immune responses, and at least one influences calcium balance.²⁶ This is part of why CgA rises in heart failure: the protein’s processing in heart tissue becomes abnormal, leading to accumulation rather than proper conversion into its active fragments.¹⁵ Researchers are exploring whether measuring specific CgA-derived peptides, rather than the intact molecule, might improve diagnostic accuracy in the future. For now, these fragments remain mostly a research interest, but they help explain why CgA shows up in so many seemingly unrelated conditions: the protein touches multiple organ systems through its breakdown products.

Interestingly, CgA levels do not appear to differ between fasting and non-fasting individuals, nor between men and women in at least one well-designed study of pre-analytical factors.²⁷ That simplifies test preparation somewhat, though intense physical exercise does temporarily raise salivary CgA.²⁸ For the blood test most clinicians order, fasting is generally not required.

1
The Journal of Clinical Endocrinology & Metabolism. Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the α-Subunit of Glycoprotein Hormones
2
PubMed. Chromogranin A in the early steps of the neurosecretory pathway
3
Journal of Clinical Laboratory Analysis. Development of a microplate assay for serum chromogranin A (CgA): Establishment of normal reference values and detection of elevated CgA in malignant diseases
4
PubMed. Paediatric reference ranges for plasma chromogranin A
5
PubMed Central. Chromogranin A as a Biochemical Marker for Neuroendocrine Tumors: A Single Center Experience at Royal Hospital, Oman
6
PLOS ONE. Diagnostic Value of Circulating Chromogranin A for Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
7
PubMed. Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors
8
The Journal of Clinical Investigation. Chromogranin A in children with neuroblastoma. Serum concentration parallels disease stage and predicts survival.
9
PubMed. Relationship between renal function and blood level of chromogranin A
10
Kidney International. Chromogranin A in uremia: Progressive retention of immunoreactive fragments
11
The Journal of Clinical Endocrinology & Metabolism. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction
12
PubMed. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition
13
PubMed. Effect of proton-pump inhibitor therapy on serum chromogranin a level
14
PubMed Central. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours
15
PubMed Central. Rethinking chromogranin A: unveiling gastrointestinal factors beyond neuroendocrine neoplasms—a narrative review
16
PubMed. Plasma chromogranin a in patients with inflammatory bowel disease
17
PubMed. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers
18
PubMed. Chromogranin A–biological function and clinical utility in neuro endocrine tumor disease
19
PubMed. A comparison between three commercial kits for chromogranin A measurements
20
The Journal of Applied Laboratory Medicine. Evaluation of CisBio ELISA for Chromogranin A Measurement
21
Clinica Chimica Acta. A chromogranin A ELISA absent of an apparent high-dose hook effect observed in other chromogranin A ELISAs
22
Journal of Pharmaceutical and Biomedical Analysis. Non-invasive screening for neuroendocrine tumors—Biogenic amines as neoplasm biomarkers and the potential improvement of “gold standards”
23
Frontiers in Oncology. The Prognostic and Predictive Role of Chromogranin A in Gastroenteropancreatic Neuroendocrine Tumors – A Single-Center Experience
24
PubMed Central. Chromogranin A as a predictor of radiological disease progression in neuroendocrine tumours
25
The Journal of Clinical Endocrinology & Metabolism. Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies
26
PubMed Central. Biological function and clinical relevance of chromogranin A and derived peptides
27
PubMed. Preanalytical factors of importance for measurement of Chromogranin A
28
PubMed Central. Salivary alpha amylase not chromogranin A reflects sympathetic activity: exercise responses in elite male wheelchair athletes with or without cervical spinal cord injury